Peringatan Keamanan

-Flunarizine should be used with care in patients with depression or those being prescribed other agents, such as phenothiazines, concurrently, which may cause extrapyramidal side-effects.
-Acute overdosage has been reported and the observed symptoms were sedation, agitation and tachycardia.
-Treatment of acute overdosage consists of charcoal administration, induction of emesis or gastric lavage, and supportive measures. No specific antidote is known.

Flunarizine

DB04841

small molecule approved

Deskripsi

Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.

Struktur Molekul 2D

Berat 404.4948
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 18 days
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

85% following oral administration.

Metabolisme

Hepatic, to two metabolites via N-dealylation and hydroxylation.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol.
  • 2. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1769 Data
Ceritinib Flunarizine may increase the bradycardic activities of Ceritinib.
Ivabradine Flunarizine may increase the bradycardic activities of Ivabradine.
Ruxolitinib Ruxolitinib may increase the bradycardic activities of Flunarizine.
Deferasirox The serum concentration of Flunarizine can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Flunarizine can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Flunarizine can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Flunarizine can be decreased when it is combined with Teriflunomide.
Buprenorphine Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Hydrocodone Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Magnesium sulfate The therapeutic efficacy of Flunarizine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Flunarizine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Mirtazapine Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Orphenadrine Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Pramipexole Flunarizine may increase the sedative activities of Pramipexole.
Ropinirole Flunarizine may increase the sedative activities of Ropinirole.
Rotigotine Flunarizine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Flunarizine.
Sodium oxybate Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Thalidomide Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Flunarizine can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Flunarizine can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Flunarizine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phenytoin The therapeutic efficacy of Flunarizine can be increased when used in combination with Phenytoin.
Fosphenytoin The therapeutic efficacy of Flunarizine can be increased when used in combination with Fosphenytoin.
Topotecan Flunarizine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Cimetidine The serum concentration of Flunarizine can be increased when it is combined with Cimetidine.
Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Flunarizine.
Efavirenz The serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.
Melatonin The therapeutic efficacy of Flunarizine can be decreased when used in combination with Melatonin.
Nafcillin The therapeutic efficacy of Flunarizine can be decreased when used in combination with Nafcillin.
Nitroprusside Flunarizine may increase the hypotensive activities of Nitroprusside.
Benzylpenicilloyl polylysine Flunarizine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Flunarizine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Flunarizine.
Dantrolene The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Flunarizine.
Lithium citrate The risk or severity of adverse effects can be increased when Flunarizine is combined with Lithium citrate.
Lithium carbonate The risk or severity of adverse effects can be increased when Flunarizine is combined with Lithium carbonate.
Lithium hydroxide The risk or severity of adverse effects can be increased when Flunarizine is combined with Lithium hydroxide.
Carbamazepine The serum concentration of Flunarizine can be decreased when it is combined with Carbamazepine.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Flunarizine.
Mirabegron The serum concentration of Flunarizine can be increased when it is combined with Mirabegron.
Boceprevir The serum concentration of Flunarizine can be increased when it is combined with Boceprevir.
Abiraterone The serum concentration of Flunarizine can be increased when it is combined with Abiraterone.
Cyproterone acetate The metabolism of Flunarizine can be increased when combined with Cyproterone acetate.
Ethanol Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.
Citalopram The risk or severity of adverse effects can be increased when Flunarizine is combined with Citalopram.
Trazodone The risk or severity of adverse effects can be increased when Flunarizine is combined with Trazodone.
Sertraline The risk or severity of adverse effects can be increased when Flunarizine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Flunarizine is combined with Sibutramine.
Zimelidine The risk or severity of adverse effects can be increased when Flunarizine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Flunarizine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Flunarizine is combined with Milnacipran.
Desvenlafaxine The serum concentration of Flunarizine can be increased when it is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Flunarizine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Flunarizine is combined with Indalpine.
Alaproclate The risk or severity of adverse effects can be increased when Flunarizine is combined with Alaproclate.
Amphetamine Amphetamine may decrease the sedative activities of Flunarizine.
Phentermine Phentermine may decrease the sedative activities of Flunarizine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Flunarizine.
Benzphetamine Benzphetamine may decrease the sedative activities of Flunarizine.
Diethylpropion Diethylpropion may decrease the sedative activities of Flunarizine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Flunarizine.
Mephentermine Mephentermine may decrease the sedative activities of Flunarizine.
MMDA MMDA may decrease the sedative activities of Flunarizine.
Midomafetamine Midomafetamine may decrease the sedative activities of Flunarizine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Flunarizine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Flunarizine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Flunarizine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Flunarizine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Flunarizine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Flunarizine.
Metamfetamine Metamfetamine may decrease the sedative activities of Flunarizine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Flunarizine.
Ritobegron Ritobegron may decrease the sedative activities of Flunarizine.
Mephedrone Mephedrone may decrease the sedative activities of Flunarizine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Flunarizine.
Gepefrine Gepefrine may decrease the sedative activities of Flunarizine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Flunarizine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Flunarizine.
Ibutilide Ibutilide may increase the arrhythmogenic activities of Flunarizine.
Adenosine Adenosine may increase the arrhythmogenic activities of Flunarizine.
Levosimendan Levosimendan may increase the arrhythmogenic activities of Flunarizine.
Ajmaline Ajmaline may increase the arrhythmogenic activities of Flunarizine.
Carteolol Flunarizine may increase the arrhythmogenic activities of Carteolol.
Metipranolol Flunarizine may increase the arrhythmogenic activities of Metipranolol.
Azimilide Flunarizine may increase the arrhythmogenic activities of Azimilide.

Target Protein

Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A
Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G
Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H
Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I
Calmodulin CALM1
Histamine H1 receptor HRH1

Referensi & Sumber

Synthesis reference: Matthew Peterson, Julius Remenar, Carlos Sanrame, "NOVEL FLUNARIZINE SALT FORMS AND METHODS OF MAKING AND USING THE SAME." U.S. Patent US20080200474, issued August 21, 2008.

Contoh Produk & Brand

Produk: 3 • International brands: 5
Produk
  • Flunarizine
    Capsule • 5 mg • Oral • Canada • Approved
  • Novo-flunarizine - Cap 5mg
    Capsule • 5 mg • Oral • Canada • Generic • Approved
  • Sibelium Cap 5mg
    Capsule • 5 mg • Oral • Canada • Approved
International Brands
  • Flugeral — Italfarmaco
  • Fluxarten — GlaxoSmithKline
  • Gradient — Polifarma
  • Sibelium — Janssen
  • Zinasen — AtralCipan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul